The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Bengt I. Eriksson

Department of Ortopaedics

Institute of Clinical Sciences

University of Gothenburg

Sahlgrenska University Hospital

Sweden. Electronic address:

[email]@orthop.gu.se

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Ortopaedics, Institute of Clinical Sciences, University of Gothenburg, Sahlgrenska University Hospital, Sweden. Electronic address:. 2012
  • University Hospital Sahlgrenska, Gothenburg, Sweden. 2009 - 2012
  • University of Gothenburg, Department of Orthopaedics, Sahlgrenska University Hospital, Mölndal, Sweden. 2001 - 2011

References

  1. Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: A pooled analysis. Eriksson, B.I., Dahl, O.E., Feuring, M., Clemens, A., Noack, H., Hantel, S., Friedman, R.J., Huo, M. Thromb. Res. (2012) [Pubmed]
  2. Evaluation of the acute coronary syndrome safety profile of dabigatran etexilate in patients undergoing major orthopedic surgery: findings from four Phase 3 trials. Eriksson, B.I., Smith, J.J., Caprini, J., Hantel, S., Clemens, A., Feuring, M., Schnee, J., Barsness, G.W. Thromb. Res. (2012) [Pubmed]
  3. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Eriksson, B.I., Dahl, O.E., Huo, M.H., Kurth, A.A., Hantel, S., Hermansson, K., Schnee, J.M., Friedman, R.J. Thromb. Haemost. (2011) [Pubmed]
  4. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Eriksson, B.I., Quinlan, D.J., Eikelboom, J.W. Annu. Rev. Med. (2011) [Pubmed]
  5. Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2). Eriksson, B.I., Turpie, A.G., Lassen, M.R., Prins, M.H., Agnelli, G., Kälebo, P., Wetherill, G., Wilpshaar, J.W., Meems, L. J. Thromb. Haemost. (2010) [Pubmed]
  6. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Eriksson, B.I., Quinlan, D.J., Weitz, J.I. Clin. Pharmacokinet (2009) [Pubmed]
  7. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. Eriksson, B.I., Kakkar, A.K., Turpie, A.G., Gent, M., Bandel, T.J., Homering, M., Misselwitz, F., Lassen, M.R. J. Bone. Joint. Surg. Br (2009) [Pubmed]
  8. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. Eriksson, B.I., Borris, L.C., Friedman, R.J., Haas, S., Huisman, M.V., Kakkar, A.K., Bandel, T.J., Beckmann, H., Muehlhofer, E., Misselwitz, F., Geerts, W. N. Engl. J. Med. (2008) [Pubmed]
  9. Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study. Eriksson, B.I., Dahl, O.E., Lassen, M.R., Ward, D.P., Rothlein, R., Davis, G., Turpie, A.G. J. Thromb. Haemost. (2008) [Pubmed]
  10. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. Eriksson, B.I., Dahl, O.E., Rosencher, N., Kurth, A.A., van Dijk, C.N., Frostick, S.P., Kälebo, P., Christiansen, A.V., Hantel, S., Hettiarachchi, R., Schnee, J., Büller, H.R. J. Thromb. Haemost. (2007) [Pubmed]
  11. A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. Eriksson, B.I., Turpie, A.G., Lassen, M.R., Prins, M.H., Agnelli, G., Kälebo, P., Gaillard, M.L., Meems, L. J. Thromb. Haemost. (2007) [Pubmed]
  12. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Eriksson, B.I., Dahl, O.E., Rosencher, N., Kurth, A.A., van Dijk, C.N., Frostick, S.P., Prins, M.H., Hettiarachchi, R., Hantel, S., Schnee, J., Büller, H.R. Lancet (2007) [Pubmed]
  13. Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement. Eriksson, B.I., Borris, L.C., Dahl, O.E., Haas, S., Huisman, M.V., Kakkar, A.K., Misselwitz, F., Muehlhofer, E., Kälebo, P. Thromb. Res. (2007) [Pubmed]
  14. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. Eriksson, B.I., Borris, L., Dahl, O.E., Haas, S., Huisman, M.V., Kakkar, A.K., Misselwitz, F., Kälebo, P. J. Thromb. Haemost. (2006) [Pubmed]
  15. Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgery. Eriksson, B.I., Quinlan, D.J. Drugs (2006) [Pubmed]
  16. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Eriksson, B.I., Borris, L.C., Dahl, O.E., Haas, S., Huisman, M.V., Kakkar, A.K., Muehlhofer, E., Dierig, C., Misselwitz, F., Kälebo, P. Circulation (2006) [Pubmed]
  17. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. Eriksson, B.I., Dahl, O.E., Büller, H.R., Hettiarachchi, R., Rosencher, N., Bravo, M.L., Ahnfelt, L., Piovella, F., Stangier, J., Kälebo, P., Reilly, P. J. Thromb. Haemost. (2005) [Pubmed]
  18. Ximelagatran in orthopaedic surgery. Eriksson, B. Pathophysiol. Haemost. Thromb. (2005) [Pubmed]
  19. Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors. Eriksson, B.I., Dahl, O.E. Drugs (2004) [Pubmed]
  20. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. Eriksson, B.I., Dahl, O.E., Ahnfelt, L., Kälebo, P., Stangier, J., Nehmiz, G., Hermansson, K., Kohlbrenner, V. J. Thromb. Haemost. (2004) [Pubmed]
  21. Clinical experience with ximelagatran in orthopaedic surgery. Eriksson, B. Drugs (2004) [Pubmed]
  22. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Eriksson, B.I., Agnelli, G., Cohen, A.T., Dahl, O.E., Mouret, P., Rosencher, N., Eskilson, C., Nylander, I., Frison, L., Ogren, M. Thromb. Haemost. (2003) [Pubmed]
  23. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Eriksson, B.I., Lassen, M.R. Arch. Intern. Med. (2003) [Pubmed]
  24. Clinical experience of melagatran/ximelagatran in major orthopaedic surgery. Eriksson, B.I. Thromb. Res. (2003) [Pubmed]
  25. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. Eriksson, B.I., Agnelli, G., Cohen, A.T., Dahl, O.E., Lassen, M.R., Mouret, P., Rosencher, N., Kälebo, P., Panfilov, S., Eskilson, C., Andersson, M., Freij, A. J. Thromb. Haemost. (2003) [Pubmed]
  26. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery. Eriksson, B.I., Arfwidsson, A.C., Frison, L., Eriksson, U.G., Bylock, A., Kälebo, P., Fager, G., Gustafsson, D. Thromb. Haemost. (2002) [Pubmed]
  27. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Eriksson, B.I., Bergqvist, D., Kälebo, P., Dahl, O.E., Lindbratt, S., Bylock, A., Frison, L., Eriksson, U.G., Welin, L., Gustafsson, D. Lancet (2002) [Pubmed]
  28. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. Eriksson, B.I., Bauer, K.A., Lassen, M.R., Turpie, A.G. N. Engl. J. Med. (2001) [Pubmed]
 
WikiGenes - Universities